U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H47N5O7S2
Molecular Weight 749.9427
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SIMEPREVIR

SMILES

CC(C)c1csc(-c2cc(c3ccc(c(C)c3n2)OC)O[C@]4([H])C[C@]5([H])[C@@]([H])(C4)C(=O)N(C)CCCC/C(/[H])=C(/[H])\[C@]6([H])C[C@@]6(C(=NS(=O)(=O)C7CC7)O)N=C5O)n1

InChI

InChIKey=JTZZSQYMACOLNN-VDWJNHBNSA-N
InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1

HIDE SMILES / InChI

Molecular Formula C38H47N5O7S2
Molecular Weight 749.9427
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor approved for the treatment of Chronic Hepatitis C (genotype 1 and 4). Inhibiting NS3/4A, simeprevir blocks viral replication. In in vitro assays simeprevir was potent against HCV genotype 1a and 1b. Simeprevir must not be administered as monotherapy and should only be prescribed with both peginterferon alfa and ribavirin.

CNS Activity

Curator's Comment:: There was minimal penetration of the blood-brain barrier.

Originator

Curator's Comment:: Patent application WO2008092954A2 is a formulation patent, originally filed by Tibotec Pharmaceuticals, now part of Janssen Pharmaceuticals. The application claims a crystalline form of a substituted macro cyclic compound, preferably a variant of simeprevir, useful for the treatment of HCV infections.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q91RS4_9HEPC
0.359999999999999987 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OLYSIO

Approved Use

Indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or 4 infection as a component of a combination antiviral treatment regimen. OLYSIO monotherapy is not recommended.

Launch Date

1385078400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11470 ng/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2304 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4067 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6172 ng/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
206000 ng × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
24630 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
56430 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79710 ng × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41.32 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.04 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Other AEs: Headache, Diarrhoea...
Other AEs:
Headache (13.5%)
Diarrhoea (10.8%)
Fatigue (10.8%)
Pruritus (10.8%)
Anorexia (8.1%)
Back pain (8.1%)
Myalgia (8.1%)
Sources:
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, 24.0 years(range: 20-44 years)
Health Status: healthy
Age Group: 24.0 years(range: 20-44 years)
Sex: M+F
Sources:
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 38.0 years (range: 23-55 years)
Health Status: healthy
Age Group: 38.0 years (range: 23-55 years)
Sex: M
Sources:
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 38.0 years (range: 25-54 years)
Health Status: healthy
Age Group: 38.0 years (range: 25-54 years)
Sex: M+F
Sources:
Other AEs: Photosensitivity reaction, Diarrhea...
Other AEs:
Photosensitivity reaction (3 patients)
Diarrhea (2 patients)
Abdominal pain upper (2 patients)
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Disc. AE: Pruritus, Psoriasis...
AEs leading to
discontinuation/dose reduction:
Pruritus (<1%)
Psoriasis (<1%)
Rash (1%)
Rash erythematous (<1%)
Skin burning sensation (<1%)
Aggression (<1%)
Blood bilirubin increased (<1%)
Major depression (<1%)
Stomatitis (<1%)
Headache (<1%)
Pain (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhoea 10.8%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Fatigue 10.8%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Pruritus 10.8%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Headache 13.5%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Anorexia 8.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Back pain 8.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Myalgia 8.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 18–70 years
Health Status: unhealthy
Age Group: 18–70 years
Sex: M+F
Sources:
Abdominal pain upper 2 patients
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 38.0 years (range: 25-54 years)
Health Status: healthy
Age Group: 38.0 years (range: 25-54 years)
Sex: M+F
Sources:
Diarrhea 2 patients
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 38.0 years (range: 25-54 years)
Health Status: healthy
Age Group: 38.0 years (range: 25-54 years)
Sex: M+F
Sources:
Photosensitivity reaction 3 patients
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 38.0 years (range: 25-54 years)
Health Status: healthy
Age Group: 38.0 years (range: 25-54 years)
Sex: M+F
Sources:
Rash 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Aggression <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Blood bilirubin increased <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Headache <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Major depression <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Pain <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Pruritus <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Psoriasis <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Rash erythematous <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Skin burning sensation <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
Stomatitis <1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 18-73 years)
Health Status: unhealthy
Age Group: 49 years (range: 18-73 years)
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [IC50 42.9 uM]
moderate [IC50 49.1 uM]
moderate [IC50 59.7 uM]
no
no
no
no
no
weak [IC50 131 uM]
likely (co-administration study)
Comment: Concomitant use of OLYSIO with these antiarrhythmics may result in mild increases in concentrations of these antiarrhythmics due to intestinal CYP3A4 inhibition by simeprevir
Page: 37
weak [IC50 86.1 uM]
yes [IC50 1.67 uM]
yes [IC50 25 uM]
yes (co-administration study)
Comment: Concomitant use of OLYSIO with rosuvastatin resulted in increased plasma concentrations of rosuvastatin due to inhibition of OATP1B1 by simeprevir
Page: 38
yes [IC50 3.47 uM]
yes [IC50 6.4 uM]
yes [IC50 85.9 uM]
yes (co-administration study)
Comment: Concomitant use of OLYSIO with digoxin resulted in increased concentrations of digoxin due to inhibition of P-gp by simeprevir
Page: 38
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes
yes
yes
likely (co-administration study)
Comment: Concomitant use of OLYSIO with carbamazepine, oxcarbazepine, phenobarbital or phenytoin may result in significantly decreased plasma concentrations of simeprevir due to strong CYP3A induction by these anticonvulsants; Concomitant use of OLYSIO with clarithromycin or telithromycin may result in increased plasma concentrations of simeprevir due to CYP3A inhibition by these antibiotics
Page: 37
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
2009 Apr
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
2010 Jul 15
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
2011 Sep
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
2012 Apr 12
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
2012 Dec 15
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
2014 Feb
Changing the face of hepatitis C management - the design and development of sofosbuvir.
2015
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
2015 Aug 5
Hepatitis C virus: Virology, diagnosis and treatment.
2015 Jun 8
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
2015 Sep
Patents

Sample Use Guides

The recommended dose is one 150 mg capsule taken once daily with food. OLYSIO should be administered with both peginterferon alfa and ribavirin. The recommended treatment duration of OLYSIO with peginterferon alfa and ribavirin is 12 weeks, followed by either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on prior response status.
Route of Administration: Oral
The median simeprevir EC50 and EC90 values against a HCV genotype 1b replicon were 9.4 nM (7.05 ng/mL) and 19 nM (14.25 ng/mL), respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:06:51 UTC 2021
Edited
by admin
on Sat Jun 26 10:06:51 UTC 2021
Record UNII
9WS5RD66HZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SIMEPREVIR
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
TMC435
Common Name English
TMC435350
Code English
TMC 435350
Code English
TMC 435
Code English
SIMEPREVIR [VANDF]
Common Name English
SIMEPREVIR [JAN]
Common Name English
SIMEPREVIR [INN]
Common Name English
SIMEPREVIR SODIUM [JAN]
Common Name English
TMC-435
Code English
SIMEPREVIR [USAN]
Common Name English
SIMEPREVIR [WHO-DD]
Common Name English
SIMEPREVIR [MI]
Common Name English
TMC-435350
Code English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
WHO-ATC J05AP05
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
WHO-ATC J05AE14
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
NDF-RT N0000182639
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
Code System Code Type Description
NDF-RT
N0000182638
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY HCV NS3/4A Protease Inhibitors [MoA]
FDA UNII
9WS5RD66HZ
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
NCI_THESAURUS
C129015
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
DRUG BANK
DB06290
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
WIKIPEDIA
Simeprevir
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
IUPHAR
7367
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
DRUG CENTRAL
4812
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
PUBCHEM
24873435
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
ChEMBL
CHEMBL501849
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
CAS
1217263-04-1
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
CAS
923604-59-5
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
NDF-RT
N0000190107
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
INN
9432
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
LACTMED
Simeprevir
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
HSDB
8227
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
EVMPD
SUB64783
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
MERCK INDEX
M11694
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY
RXCUI
1482790
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000190108
Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
PRIMARY Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
Related Record Type Details
TARGET -> INHIBITOR
INHIBITOR
EXCRETED UNCHANGED
Results from the mass balance trial demonstrated that the majority of the simeprevir dose is absorbed, with only 31.0% of dose excreted as unchanged drug in the feces (Trial C103).
FECAL
METABOLIC ENZYME -> INHIBITOR
WEAK
IC50
TRANSPORTER -> INHIBITOR
Simeprevir inhibited P-gp-dependent transport of paclitaxel in Caco-2 cells with an IC50 value of 64.4 ug/mL (Study NC113).
IC50
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
Specifically used for hepatitis C genotype 1 and 4.
METABOLIC ENZYME -> INHIBITOR
WEAK
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Plasma concentration will significantly increase if taken with medications that are strong CYP3A4 inhibitors (i.e. erythromycin, ritonavir) and will significantly decrease if taken with strong CYP3A4 inducers (i.e. efavirenz, rifampin, Saint John's wort).
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
CYP2C8
IC50
METABOLIC ENZYME -> INHIBITOR
MODERATE
IC50
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> INHIBITOR
CYP2C8
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC